Theravance Biopharma, Inc.
TBPH
Jodie situation report
Theravance Biopharma, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 12 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ATAI begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind TBPH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
VTRSViatris Inc.partnerMay 7, 2026 ▾
“The stability of revefenacin in both metered dose inhaler and dry powder inhaler (“MDI/DPI”) formulations suggests that revefenacin could also serve as a foundation for novel handheld combination products.”
RPRXRoyalty Pharma plcinvesteeMay 7, 2026 ▾
“Royalty Pharma’s $40.0 million investment in ampreloxetine included a $25.0 million upfront payment received in July 2022 and an additional $15.0 million payment upon the first regulatory approval of ampreloxetine.”
Depended on by
VTRSViatris Inc.partnerFeb 26, 2026 ▾
“Theravance Biopharma The Company has a development and commercialization collaboration with Theravance Biopharma, for revefenacin.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TBPH is currently a Participant in the organic co-movement group Biotech Cancer Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.